Lyon Joseph Douglas sold $1.1M of CORT

Lyon Joseph Douglas (See Remarks) sold 10,000 shares of CORCEPT THERAPEUTICS INC (CORT) at an average of $113.49 ($113.32–$114.12, $1.13M total) across 2 trades on 2026-09-14 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Lyon Joseph Douglas
Published Sep 16, 2026, 8:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 16, 2026, 9:17 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$CORT
Neutral
high confidence
Mentioned
$CORT
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CORTNeutralLow
01

Why it matters

The transaction modestly reduces insider ownership but is unlikely to affect market perception.

02

Market read

Low relevance; primarily informational for shareholders tracking insider activity.

03

What to watch

Potential upcoming clinical data releases could change the relevance of insider holdings.

Relevance 5/10Novelty 4/10Timing: filed Sep 16 2026

Background

Form 4 filings disclose insider transactions; this filing reports a routine sale under a 10b5‑1 plan.

Company-level read

Ticker impact

$CORTNeutralHigh confidence
Context

Officer Lyon Joseph Douglas sold 10,000 shares for $1.13M via a 10b5-1 plan, reducing his stake to 5,683 shares.

Expected impact

No significant price impact expected.

Evidence & confidence

The sale size is modest relative to market cap and follows a pre‑arranged plan.

Market effects

None; insider sale does not affect the broader pharma sector.

No regional impact.

Limited to Corcept Therapeutics investors.

Counterpoint

If the insider is signaling lack of confidence, a short‑term dip could be considered.

Key entities

  • Corcept Therapeutics Inc.

    Biopharmaceutical company developing cortisol‑targeting therapies.

  • Lyon Joseph Douglas

    Company officer who sold shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$CORTMedAI 8/10

Corcept reports 8-year response in vulvar cancer case study

Corcept Therapeutics (CORT) reported a case study in ESMO Rare Cancers showing an 8-year response to relacorilant plus nab-paclitaxel in a metastatic vulvar cancer patient. The company noted this is a single case and not representative of the broader population. Relacorilant is FDA-approved for platinum-resistant ovarian cancer but not vulvar cancer. Corcept is developing the drug for other cancer types.

$CORTMed

Corcept Therapeutics Inc (CORT) (Q3 2026) Earnings Call Highlights: Revenue Surges 64%

Corcept Therapeutics (CORT) reported Q3 2026 revenue of $91M, up 64% YoY, driven by Lifyorli's growth. Management expects Lifyorli to move earlier in treatment sequences and sees potential for $1B in revenue. The company reiterated its 2026 guidance of $1.1B-$1.2B, citing strong performance in endocrinology and oncology. CEO Belanoff discussed upcoming clinical trials and potential combinations for Lifyorli.

$CORTMedAI 8/10

Corcept Therapeutics Q3 Earnings Call Highlights

Corcept Therapeutics (CORT) reported positive results from its BELLA Phase 2 trial, with relacorilant showing median progression-free survival of 7.2 months and a 59% response rate. The FDA is set to decide on relacorilant's application for Cushing's syndrome by December 17. Corcept also outlined ongoing trials for relacorilant in various cancers and miricorilant in MASH, with results expected by 2027. The company plans to initiate a Phase 3 ALS study next year.